Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
SSY Group ( (HK:2005) ) has shared an announcement.
SSY Group Limited announced that its drug Piribedil has received approval from China’s National Medical Products Administration as a bulk drug for market preparations. This marks the third such approval for the company’s PRC entities, reflecting a notable advancement in its product offerings and potential to enhance its market position in treating Parkinson’s disease.
More about SSY Group
SSY Group Limited operates within the pharmaceutical industry, focusing on the development and production of drugs. Its products primarily target treatments for diseases such as Parkinson’s and address circulatory disturbances, with a significant market focus in China.
YTD Price Performance: -1.16%
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $1.26B
Find detailed analytics on 2005 stock on TipRanks’ Stock Analysis page.
